Our top pick for
Annovis Bio, Inc is a biotechnology business based in the US. Annovis Bio shares (ANVS) are listed on the NYSE MKT and all prices are listed in US Dollars. Annovis Bio employs 2 staff and has a market cap (total outstanding shares value) of USD$194.6 million.
|52-week range||USD$2.42 - USD$34.2|
|50-day moving average||USD$15.0509|
|200-day moving average||USD$7.6862|
|Wall St. target price||USD$16|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.1626|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-71.58%|
|Return on equity TTM||-101.21%|
|Market capitalisation||USD$194.6 million|
TTM: trailing 12 months
There are currently 41,187 Annovis Bio shares held short by investors – that's known as Annovis Bio's "short interest". This figure is 28.3% down from 57,451 last month.
There are a few different ways that this level of interest in shorting Annovis Bio shares can be evaluated.
Annovis Bio's "short interest ratio" (SIR) is the quantity of Annovis Bio shares currently shorted divided by the average quantity of Annovis Bio shares traded daily (recently around 98064.285714286). Annovis Bio's SIR currently stands at 0.42. In other words for every 100,000 Annovis Bio shares traded daily on the market, roughly 420 shares are currently held short.
However Annovis Bio's short interest can also be evaluated against the total number of Annovis Bio shares, or, against the total number of tradable Annovis Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Annovis Bio's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Annovis Bio shares in existence, roughly 10 shares are currently held short) or 0.0095% of the tradable shares (for every 100,000 tradable Annovis Bio shares, roughly 10 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Annovis Bio.
Find out more about how you can short Annovis Bio stock.
We're not expecting Annovis Bio to pay a dividend over the next 12 months.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.